The Effects of Extrafine Beclometasone/Formoterol (BDP/F) on Lung Function, Dyspnea, Hyperinflation, and Airway Geometry in COPD Patients: Novel Insight Using Functional Respiratory Imaging

Jan De Backer, MSc, PhD, Wim Vos, MSc, PhD, Samir Vinchurkar, MSc, PhD, Cedric Van Holsbeke, MSc, PhD, Gianluigi Poli, MSc, PhD, Rita Claes, BSc, Rodrigo Salgado, MD, PhD, and Wilfried De Backer, MD, PhD

Abstract
Background: The efficacy of inhaled corticosteroids (ICS) in moderately severe COPD patients remains unclear. At the same time, the use of extrafine particles in COPD patients is a topic of ongoing research.

Objectives: This study assessed the effect of ICS in steroid-naive mild COPD patients and the effect of reducing the ICS dose in more severe COPD patients previously using ICS when switching to an extrafine particle BDP/F formulation (Foster using Modulite technology, Chiesi Pharmaceutici, Parma, Italy).

Methods: Novel functional respiratory imaging (FRI) methods, consisting of multi-slice CT scans and Computational Fluid Dynamics, were used in combination with conventional pulmonary function tests and patient reported outcomes.

Results: The study showed that the administration of extrafine BDP/F after 4–6 h led to a significant improvement in lung function parameters and hyperinflation as determined by spirometry, body plethysmography, and functional respiratory imaging. After 6 months of treatment, it was observed that, compared to baseline, the hyperinflation on lobar level at total lung capacity was significantly reduced ($-1.19 \pm 7.19 \% p, p = 0.009$). In addition, a significant improvement in SGRQ symptom score was noted in the entire patient population. Patients who improved in terms of hyperinflation also improved their MMRC dyspnea score. CFD indicated a difference in regional deposition between extrafine and non-extrafine formulations with $-11\%$ extrathoracic deposition and up to $+4\%$ lobe deposition for the extrafine formulation.

Conclusions: The study showed that the administration of extrafine BDP/F improved lung function parameters and hyperinflation. Patients previously treated with ICS remained stable despite the lower dose, while ICS naive patients improved in terms of lobar hyperinflation. FRI seems to be a sensitive biomarker to detect clinically relevant changes that are not detected by spirometry. The next step is to confirm these findings in a controlled trial.

Introduction

Chronic obstructive pulmonary disease (COPD) is a multicomponent disease that includes airway inflammation, airflow limitation, mucociliary dysfunction, and airway structural changes. The hallmark of COPD is, beside the destruction of the lung tissue and capillaries, expiratory flow limitation, which is slowly progressive and irreversible. Specific lung function tests, including flow-volume loops, $N_2$ wash-out, and helium flow-volume loops, are typically performed to evaluate the small airway function. Recently, advanced imaging techniques such as multi-slice high resolution CT have been used. This technique allows evaluation of the density of the parenchyma and
reconstruction of the airways in 3D. Very recently, we developed a functional respiratory imaging (FRI) technique combining CT imaging with computational fluid dynamics (CFD). With CFD, based on the CT-derived geometry of the airways, it became possible not only to reconstruct the geometry of the distal airways but also to measure the overall resistance of airways and regional aerosol deposition characteristics at the more peripheral level such as the smaller airways starting from the third bifurcation. Lung volumes can be assessed in more detail at the lobar level, leading to a more granular description of hyperinflation. In previous studies, we demonstrated very good correlations between spirometric indices such as Forced Expiratory Volume in one second (FEV1) and FEV1/FVC (Forced Vital Capacity) index with the FRI parameters. Therefore, the use of FRI may allow following the functional and anatomic changes in the small

Table 1. Patient Demographics and Baseline Pre-Bronchodilation Lung Function and SGRQ

<table>
<thead>
<tr>
<th></th>
<th>GOLD II (n=15)</th>
<th>GOLD III (n=8)</th>
<th>GOLD IV (n=4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age [years]</td>
<td>64.67 ± 8.06</td>
<td>62.37 ± 7.11</td>
<td>67.25 ± 12.28</td>
</tr>
<tr>
<td>FEV1 [%pred]</td>
<td>52.94 ± 11.38</td>
<td>37.25 ± 10.07</td>
<td>38.25 ± 16.50</td>
</tr>
<tr>
<td>FEV1/VC [%]</td>
<td>43.13 ± 9.43</td>
<td>35.00 ± 8.37</td>
<td>40.00 ± 13.78</td>
</tr>
<tr>
<td>SGRQ [-]</td>
<td>44.52 ± 16.78</td>
<td>44.79 ± 15.10</td>
<td>48.15 ± 11.07</td>
</tr>
<tr>
<td>FRC [%pred]</td>
<td>150.27 ± 28.07</td>
<td>160.13 ± 28.27</td>
<td>146.50 ± 48.86</td>
</tr>
<tr>
<td>TLC [%pred]</td>
<td>121.13 ± 17.92</td>
<td>117.50 ± 16.56</td>
<td>114.50 ± 34.31</td>
</tr>
</tbody>
</table>

Table 2. Medication Prior to Study Inclusion and Associated Inhalers

<table>
<thead>
<tr>
<th>Nr</th>
<th>Age</th>
<th>Gender</th>
<th>Stage</th>
<th>Lung medication before V1</th>
<th>Nr</th>
<th>Age</th>
<th>Gender</th>
<th>Stage</th>
<th>Lung medication before V1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>60</td>
<td>M</td>
<td>GOLD 3</td>
<td>Serevent 25 μg 2 × 1/day</td>
<td>15</td>
<td>68</td>
<td>M</td>
<td>GOLD 3</td>
<td>Oxis 9 μg 2×1/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Spiriva</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Spiriva Duvent PRN</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pulmicort 200 μg, 2×2/day</td>
</tr>
<tr>
<td>2</td>
<td>53</td>
<td>M</td>
<td>GOLD 4</td>
<td>Seretide 25 μg/250 μg 2</td>
<td>16</td>
<td>64</td>
<td>F</td>
<td>GOLD 3</td>
<td>Spiriva Seretide 50 μg/500</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>× 2/day Spiriva Duvent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>μg 2×1/day Spiriva</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PRN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acetylcysteine 600 mg</td>
</tr>
<tr>
<td>3</td>
<td>81</td>
<td>M</td>
<td>GOLD 4</td>
<td>Serevent 50 μg 1×1/day</td>
<td>17</td>
<td>73</td>
<td>M</td>
<td>GOLD 2</td>
<td>Spiriva Acetylcysteine 600</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Spiriva</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ventolin PRN</td>
</tr>
<tr>
<td>4</td>
<td>63</td>
<td>F</td>
<td>GOLD 2</td>
<td>Spiriva</td>
<td>18</td>
<td>51</td>
<td>F</td>
<td>GOLD 2</td>
<td>Spiriva Seretide 25/250 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>× 2/day Duvent PRN</td>
</tr>
<tr>
<td>5</td>
<td>65</td>
<td>M</td>
<td>GOLD 3</td>
<td>Seretide 50 μg/500 μg 2</td>
<td>19</td>
<td>47</td>
<td>F</td>
<td>GOLD 2</td>
<td>Spiriva Seretide 50 μg 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>× 1/day Spiriva Duvent PRN)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>× 1/day Ventolin PRN</td>
</tr>
<tr>
<td>6</td>
<td>48</td>
<td>M</td>
<td>GOLD 3</td>
<td>Seretide 25 μg/250 μg 2</td>
<td>20</td>
<td>72</td>
<td>M</td>
<td>GOLD 2</td>
<td>Symbicort 4,5 μg/160 μg 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>× 2/day Spiriva Duvent PRN)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>× 1/day Spiriva</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acetylcysteine 600 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Montelukast 10mg</td>
</tr>
<tr>
<td>7</td>
<td>65</td>
<td>M</td>
<td>GOLD 3</td>
<td>Seretide 50 μg/500 μg 2</td>
<td>21</td>
<td>65</td>
<td>M</td>
<td>GOLD 2</td>
<td>Spiriva Symbicort 4,5 μg/</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>× 1/day Spiriva Duvent PRN)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>160 μg 2×2/day Duvent PRN</td>
</tr>
<tr>
<td>8</td>
<td>73</td>
<td>M</td>
<td>GOLD 2</td>
<td>Serevent 50 μg 2×1/day</td>
<td>22</td>
<td>64</td>
<td>M</td>
<td>GOLD 2</td>
<td>Spiriva Seretide 50 μg 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>× 1/day Spiriva Duvent PRN)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>× 1/day Duvent PRN</td>
</tr>
<tr>
<td>9</td>
<td>64</td>
<td>M</td>
<td>GOLD 2</td>
<td>Serevent 50 μg 2×1/day</td>
<td>23</td>
<td>63</td>
<td>F</td>
<td>GOLD 2</td>
<td>Spiriva Symbicort Forte 9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>× 1/day Spiriva Duvent PRN)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>μg/320 μg 2×1/day Duvent PRN</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>puff and aerosol</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lysomucil 600 mg PRN</td>
</tr>
</tbody>
</table>

(continued)
During the last 10 years, inhaled corticosteroids (ICS) and long-acting \( \beta_2 \) agonists (LABA) combination therapy has come forward to treat COPD patients. The concomitant use of ICS and LABA can influence airway obstruction, mucociliary dysfunction, and airway inflammation.\(^{(1,11)}\) Furthermore, use of ICS in combination with LABA in a single inhaler shows significant additional improvements on pulmonary function and reduction in symptoms and exacerbations, compared with individual components.\(^{(12-15)}\)

<table>
<thead>
<tr>
<th>Nr</th>
<th>Age</th>
<th>Gender</th>
<th>Stage</th>
<th>Lung medication before V1</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>61</td>
<td>F</td>
<td>GOLD 2</td>
<td>Spiriva Duvent PRN</td>
</tr>
<tr>
<td>11</td>
<td>62</td>
<td>F</td>
<td>GOLD 4</td>
<td>Serevent 25 ( \mu g ) ( 3 \times 1/day ) Flixotide 250 ( \mu g ) ( 3 \times 2/day ) Spiriva Duvent 2 ( \times 2/day ) Xanthium 400mg 1 ( \times 1/day )</td>
</tr>
<tr>
<td>12</td>
<td>78</td>
<td>F</td>
<td>GOLD 2</td>
<td>Oxis 9 ( \mu g ) ( 2 \times 1/day ) Spiriva Duvent 2 ( \times 2 )</td>
</tr>
<tr>
<td>13</td>
<td>62</td>
<td>F</td>
<td>GOLD 2</td>
<td>Oxis 9 ( \mu g ) ( 2 \times 1/day ) Spiriva Duvent 2 ( \times 2 )</td>
</tr>
<tr>
<td>14</td>
<td>71</td>
<td>F</td>
<td>GOLD 3</td>
<td>Spiriva Seretide 50 ( \mu g/500 \mu g ) ( 2 \times 1/day )</td>
</tr>
</tbody>
</table>

**Inhalers associated with the medication**

Serevent 25  
Serevent 50  
Spiriva Duvent  
Serevent 25/250  
Serevent 50/250  
Symbicort 9/320  
Symbicort 4.5/160  
Ventolin 100  
Pulmicort 200  
Oxis

Evohaler  
Diskus  
Respimat  
HFA MDI  
Evohaler  
Diskus  
Turbuhaler  
Turbuhaler  
Turbuhaler  
Turbuhaler

In COPD patients after 6 month treatment using pulmonary function tests and sensitive FRI tools, with specific focus on lobar and airway volumes and resistance, to assess the effect at the level of small airways. Both steroid naïve (moderate COPD patients) and steroid users (severe COPD patients) were included in the patient cohort to assess the effect of extrafine particle ICS in moderate COPD.

**Methods**

**Patients**

This study enrolled 27 evaluable COPD patients stage II to IV. Patients had a smoking history of at least 10 pack-years and an FEV1/FVC ratio below 0.70. Male (\( n = 16 \)) and female (\( n = 11 \)) patients were included with age above 40 years. All patients were treated according to the GOLD guidelines before entering the study. Patient demographics and characteristics according to GOLD classification can be found in Table 1.

**Study design**

This study was an open-label, prospective pilot study. The patients received the extrafine beclometasone dipropionate and formoterol fumarate (BDP/F) combination therapy for 24 weeks. They were followed for 7 months before the start of
the study when they switched to the extrafine formulation. During this 7-month period they were treated with inhaled steroids or fixed combinations with a non-extraneous particle formulation (i.e., no Foster or QVAR). Patients were evaluated twice for their lung function and clinical status (at 7 and 3 months before the switch). At baseline visit, patients received all tests (FRI, pulmonary function tests, and patient reported outcomes) before and after bronchodilation. At the 6 months visit, patients again received all tests before bronchodilation (pre-dose).

Medication

The study medication (Foster, Chiesi Pharmaceutici, Italy) is a fixed combination containing extrafine beclometasone dipropionate and formoterol fumarate in a HFA Modulite® pMDI device (MMAD = 1.33; GSD = 1.97). Each metered dose (ex-valve) contains 100 micrograms of beclometasone dipropionate and 6 micrograms of formoterol fumarate dihydrate. In this study, patients inhaled the 6 μg formoterol and 100 μg beclometasone dipropionate combination therapy twice in the morning and twice in the evening.

Image post-processing

The CT settings used were: tube voltage, 120 kV; tube current, 10 (low weight patients)–100 (high weight patients) mAs; noise factor, 28; collimation, 0.625 mm; rotation time, 0.6 sec; and pitch factor, 1.375. The field of view was indicated by the CT technician based on the scout image and was positioned closely around the thorax to optimize in-plane image resolution, which was approximately 0.5 mm. The resulting radiation dose was in the order of 1–2 mSv per scan. Images were reconstructed to a slice thickness of 0.6 mm to attain near cubic voxels. Respiratory gating was used to ensure the proper lung volume to facilitate comparison between baseline and follow-up images. Post-processing of the CT images included segmentation of the airway tree structure, the lung lobes, and CFD flow simulations. Segmentation consisted of grouping voxels that belong to one anatomical structure such as the lung, the lobes, or the airway tree. This group of voxels or mask can subsequently be used to create a patient-specific three-dimensional model of the anatomical structure under consideration. The software package that was used was FDA-approved (Mimics, Materialise, Leuven, Belgium). These patient specific models were the basis for flow simulations using Computational Fluid Dynamics (CFD). More details on the segmentation and CFD principles can be found in previously published studies.

Assessments

The parameters obtained with functional respiratory imaging and used as primary outcome were:

- Airway volumes specific for the lung volume (siVaw): the airway volumes are direct measurement from the CT scans and include the airways with a diameter larger than 1–2 mm. Around 255 airways are typically included in the patient specific geometry, which corresponds to around 7 generations of airways. The airway volume is a function of the lung volume. To allow comparison of the volumes at different measurement points, the airway volume is normalized by dividing by the lobe volume. The same number of airways are present the baseline and follow-up measurements (see Fig. 3).

- Specific airway resistance (siRaw): airway resistance is calculated using CFD. CT-based lobe expansion from expiration to inspiration was used as boundary conditions to ensure the internal airflow distribution in the CFD calculation matches the patient’s real internal airflow distribution. CFD yields total pressure drops and airflow, the resistance is ratio between the two. More information can be found in De Backer et al.

- Lobar volumes at functional residual capacity (iVlobes_FRC).

- Lobar volumes at total lung capacity (iVlobes_TLC).

Lobar volumes are determined by first segmenting the lung volumes and the fissures; subsequently the fissures are used as cutting planes to determine the lobe volume. The following parameters were obtained with the lung function tests:

- Dynamic lung volumes: Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), Maximal expiratory flow at 50% of expired vital capacity (MEF50), Maximal expiratory flow at 25% of expired vital capacity (MEF25).

- Static lung volumes: Vital capacity (VC), Inspiratory vital capacity (IVC), Functional residual capacity (FRC), Total lung capacity (TLC).

- Airway resistances: Airway resistance (Raw), Specific airway conductance (SGaw), based on body plethysmography.

Further assessments were:

- Functional dyspnea (MMRC dyspnea scale).

- Saint George Respiratory Questionnaire (SGRQ).

CFD based deposition analysis

To understand the changes in deposition when switching to extraneous particles, a CFD-based deposition analysis was performed in one patient. The baseline model was coupled with the inhaler of the medication the patient previously used (i.e., Oxis Turbuhaler; MMAD = 2.64; GSD = 1.91)) and with the Foster inhaler. Two CFD-based deposition analysis were performed using the methodology described and validated in De Backer et al., with the Foster inhaler in both scenarios (3 second inhalation with 60L/min peak flow).

These analyses provided regional aerosol deposition characteristics. No exhaled fraction was assumed for both scenarios.

Statistics

Statistical analysis was performed using Statistica 9.1 (StatSoft, Tulsa, OK, USA). Changes in individual parameters after 6 months of treatment with the study medication were evaluated using Wilcoxon matched pairs analysis. Correlations between the changes in different parameters were evaluated using Spearman correlations. Stability of the baseline 7-month period was evaluated with ANOVA. Data are presented as mean ± standard deviation.
FIG. 1. FEV\textsubscript{1} [L] at two time points prior to inclusion demonstrate that patients were stable and controlled before entering the study.

FIG. 2. Changes in FEV\textsubscript{1}, TLC, and FRC 4 h at pre-dose and after drug administration at Day 1 (left) and between pre-dose at D1 and after 6 months of treatment (right).
Ethics

Approval from the ethical committee of the University Hospital in Antwerp was obtained and patients all gave their informed consent (NCT01204034). The study started September 2010 and ended June 2012.

Results

Lung function during initial 7 month treatment with non-extrafine particles

All patients were treated with non-extrafine particles compounds during a 7-month period prior to the switch (Table 2). During this period, lung function measurements were performed at 7 months and 3 months prior to the switch. The results are given in Figure 1. There were no significant changes in the FEV1 during this period, nor were patients considered to be clinically unstable since their medication was not altered and their symptoms did not change significantly.

Post-bronchodilation effect 4–6 h after administration of extrafine particle compound

The data showed that, 4–6 h after the administration of the drug, FEV1 % predicted values increased significantly from 46±14% to 50±15% (p=0.0003). Concomitantly, hyperinflation decreased significantly as indicated by a reduction in FRC of 7±10%pred (p=0.002). The TLC also decreased, just missing the statistical significance threshold (p=0.06) (Fig. 2). No differences were observed between the ICS naïve patients and the ICS users for the PFTs. The FRI data showed a highly significant increase in siVaw (Fig. 3) from 0.0019±0.0001 to 0.0021±0.0001 (p<0.00001) and a highly significant reduction in siRaw from 0.23±0.26 kPas to 0.15±0.11 kPas (p<0.00001) (Fig. 4). No differences were observed between the ICS naïve patients and the ICS users for siVaw and siRaw. When assessing the changes in lobar volumes using imaging, a significant reduction was observed both in iVlobes_FRC and iVlobes_TLC (p<0.00001). ICS naïve patients reduce more in terms of acute iVlobes_FRC (p=0.0045) and iVlobes_TLC (p=0.001) compared to the ICS users.

Pre-bronchodilation effect after 6 months of treatment with the small particle compound

After 6 months of treatment, the pre-bronchodilation measures were compared with the pre-bronchodilation values at baseline. Both spirometry (FEV1) and body plethysmography values (FRC and TLC) did not change significantly (Fig. 2). Also no significant change in siVaw (p=0.65) and siRaw (p=0.16) was observed (Fig. 4). However, interestingly, the Wilcoxon matched pairs test on the imaging data at the lobar level showed a significant reduction in lobar volume at TLC (iVlobes_TLC, −1.19±7.19 %, p=0.009) (Fig. 5); this change was driven by the ICS naïve patients. A borderline

FIG. 3. Changes in siVaw [%] 4h after bronchodilation.
but significant difference in \( iVlobes_{TLC} \) change between ICS naïve patients and ICS users was observed \((p = 0.044)\). SGRQ symptoms score indicated a significant improvement \((p = 0.04)\) after 6 months (Fig. 6). The MMRC score showed a link between the change in dyspnea feeling and the change in lobar hyperinflation measured at TLC \((iVlobes_{TLC})\). Patients who reported an improvement in MMRC score equal or greater than 1 had a significantly greater \((p = 0.0024)\) reduction lobar \( iVlobes_{TLC} \) volumes compared to patients who reported a decline in MMRC by 1 or greater. The group of patients who reported no change in MMRC score had no reduction \((p > 0.05)\) in the lobar \( iVlobes_{TLC} \) level. No difference in patient reported outcome changes were observed between ICS naïve patients and ICS users. When comparing the change in pre-bronchodilation \( iVlobes_{TLC} \) with the acute (4–6 h) change in \( iVlobes_{TLC} \), a significant positive correlation \((r = 0.44, p < 0.00001)\) was observed with a slope of approximately 0.78 (Fig. 7). This would mean that around 78% of the acute, post-bronchodilation change effectively remains after 6 months of treatment. Furthermore, a highly significant negative correlation \((r = -0.40; p < 0.00001)\) was found between the pre-bronchodilation \( iVlobes_{FRC} \) and the acute change in \( iVlobes_{FRC} \) after drug intake. This indicated that the more hyperinflated the patients were prior to receiving the medication, the more they tend to deflate with treatment (Fig. 8).

**CFD-based deposition patterns**

To assess the link between the change in deposition and the change in lobar volume, CFD was used to determine the deposition patterns in patient 14. Figure 9 illustrates the coupling between the patient specific model of patient 14 and the Oxis Turbuhaler and Foster pMDI. It could be observed that the lung dose reaching the lower airways is larger for the extrafine particle formulation compared to the non-extrafine particle formulation with a reduction in extrathoracic deposition of 11% and an increase in lobe deposition up to 4% for
the extrafine particle formulation. Table 3 provides an overview of changes in deposition in relation to the changes in hyperinflation for patient 14. For this patient, it appears that more deposition correlates with reduction in hyperinflation.

**Discussion**

The current study aimed to investigate further the effect of extrafine BDP/F on airways geometry using sensitive image-based parameters in both ICS naïve patients and ICS users and to identify the responders. A recent study by Tzani et al.\(^{21}\) has indicated that the extrafine beclomethasone/formoterol combination has a beneficial effect on hyperinflation in COPD patients studied using body plethysmography (functional residual capacity, residual volume, and total lung capacity). The effect appeared to be significantly better than a fluticasone/salmeterol combination treatment. The study concluded that, by using extrafine particles, previously suboptimally or untreated regions in the lung could be reached, resulting in an enhanced efficiency. Other studies have demonstrated the added value of combining imaging and computational fluid dynamics to obtain

---

**FIG. 5.** Changes in iVlobes_TLC (%pred) 4–6 h after bronchodilation (*left, p < 0.00001*) and after 6 months of treatment with extrafine BDP/F (*right, p = 0.009*) compared to pre-bronchodilation baseline.

**FIG. 6.** Changes in SGRQ symptom score at baseline and after 6 months of treatment recorded prior to bronchodilation.
regional information on airway and lobar volumes and resistances.\(^{(8,10)}\) The image-based outcome parameters in our study confirmed the results from the previous study using BDP/F by also indicating an improvement in lung function and imaging parameters 4–6 h after the administration using this novel imaging method in patients that were proven clinically stable during at least 6 months when they were treated with non-extrafine particle compounds. The current study was a longitudinal study where subjects switched from the standard therapy including high dose of ICS/LABA or ICS naïve to a new extrafine particle drug. Further improvement in lung function and symptoms was therefore not

**FIG. 7.** Change in iVlobes_TLC [%pred] after 6 months compared to pre-dose Day 1 as a function of the changes in iVlobes_TLC [%pred] 4–6 h after the administration on Day 1.

**FIG. 8.** Change in iVlobes_FRC [%pred] 4–6 h after the administration as a function of the baseline iVlobes_FRC [%pred].
expected in the ICS users group, but adequate maintenance was an anticipated end point of the study, which was reached. The BDP/F combination used in this study contained a substantially lower dose of ICS and LABA compared to the medication that the patients received prior to the study. The enhanced lung dose due to the smaller particles and the reduced risk of pneumonia were the drivers for selecting this dose.\(^{(21)}\)

The bodyplethysmography yields aggregate or global values of TLC and FRC while FRI provides lobar information. It can happen that certain lobes reduce in hyperinflation but that the neighboring lobe re-inflates, thereby limiting the signal in the global (body box) parameters obtained using the body box. Tzani et al.\(^{(21)}\) reported significant post-dose improvements in TLC and FRC after 12 weeks. Our study looked at pre-dose TLC and FRC measurements over 6 months. Tzani’s pre-dose values over 12 weeks were not significantly different, which is in line with our findings. However, we did find significant effects on reduction in FRC after acute bronchodilation and a trend in reduction in TLC using plethysmography. On a regional, lobar level (determined using FRI) these findings become highly significant which in turn supports Tzani’s overall conclusion.

The CFD-based aerosol deposition analysis showed how the extrafine particles increase the effective lung dose and reach other areas in the lung compared to non-extrafine particle formulation. It must be stated that this analysis focused on the relative deposition differences based on the emitted dose in one patient. More effective inhalers with a larger emitted dose or different formulation characteristics could yield higher overall lung deposition compared to less effective devices. The fact that for the current analysis no exhaled fraction is assumed could imply that the extrafine particle deposition is overestimated. This will be the subject of future research. The role of ICS in moderate COPD patients has always been a topic of ongoing research. The ICS naïve patients in our study, who were considered to be more

<table>
<thead>
<tr>
<th></th>
<th>% deposition</th>
<th>Δ deposition %</th>
<th>Δ Volume FRC [%p]</th>
<th>Δ Volume TLC [%p]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxis</td>
<td>Oxis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right upper lobe</td>
<td>7</td>
<td>9</td>
<td>+2</td>
<td>−24</td>
</tr>
<tr>
<td>Right middle lobe</td>
<td>2</td>
<td>3</td>
<td>+1</td>
<td>−6</td>
</tr>
<tr>
<td>Right lower lobe</td>
<td>15</td>
<td>19</td>
<td>+4</td>
<td>−32</td>
</tr>
<tr>
<td>Left upper lobe</td>
<td>6</td>
<td>8</td>
<td>+2</td>
<td>−21</td>
</tr>
<tr>
<td>Left lower lobe</td>
<td>8</td>
<td>10</td>
<td>+2</td>
<td>−35</td>
</tr>
<tr>
<td>Extrathoracic</td>
<td>62</td>
<td>51</td>
<td>−11</td>
<td>n/a</td>
</tr>
</tbody>
</table>

**FIG. 9.** Coupling of patient 14’s airway geometry with the Oxis (left) and Foster (right) inhaler.
The study showed that the administration of extrafine BDP/F after 4–6 h leads to a significant improvement in lung function parameters and hyperinflation as determined by spirometry, body plethysmography, and functional respiratory imaging. Patients previously treated with ICS remained stable despite the lower dose, while ICS naïve patients improved in terms of lobar hyperinflation. A significant improvement in SGRQ symptom score was noted. Patients who improved in terms of hyperinflation also improved their MMRC dyspnea score. FRI seems to be a sensitive biomarker to detect clinically relevant changes that are not detected by spirometry. The next step is to confirm these findings in a controlled trial.

Conclusions

The study showed that the administration of extrafine BDP/F after 4–6 h leads to a significant improvement in lung function parameters and hyperinflation as determined by spirometry, body plethysmography, and functional respiratory imaging. Patients previously treated with ICS remained stable despite the lower dose, while ICS naïve patients improved in terms of lobar hyperinflation. A significant improvement in SGRQ symptom score was noted. Patients who improved in terms of hyperinflation also improved their MMRC dyspnea score. FRI seems to be a sensitive biomarker to detect clinically relevant changes that are not detected by spirometry. The next step is to confirm these findings in a controlled trial.

Acknowledgments

Conception and design: JDB, WV, SV, CVH, GP, RC, WDB; Analysis and interpretation: JDB, WV, SV, CVH, GP, RC, RS, WDB; Drafting the manuscript for important intellectual content: JDB, WV, SV, CVH, GP, RC, WF, RS, WDB.

Author Disclosure Statement

JDB is founder/shareholder of FluidDA nv; WV, SV, CVH are employed by FluidDA nv; WDB is director of FluidDA nv; GP is employed by Chiesi Pharmaceutical S.P.A. The study was sponsored by Chiesi Pharmaceutical S.P.A.

References


Received on May 28, 2013 in final form, April 22, 2014

Reviewed by:
Chantal Darquenne
Lars Borgström

Address correspondence to:
Jan De Backer, MSc, PhD
Fluid DA NV
Groeningenlei 132
2550 Kontich
Belgium

E-mail: Jan.DeBacker@FluidDA.com